# Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

> **NCT03608358** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 41 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Dapagliflozin 5 mg
- **DRUG:** Dapagliflozin 10 mg placebo to match
- **DRUG:** Dapagliflozin 5 mg placebo to match
- **DRUG:** Saxagliptin 5 mg
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03608358
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-27
- **Primary completion:** 2020-08-04
- **Final completion:** 2020-08-04
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Sponsor decided to stop commercialization of QTERNMet/Qtrilmet and to stop all related ongoing activities/studies for business reasons.
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608358, "Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03608358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*